GlassScriptPhysician profile
Robyn M Mccullem
NPI 1598749467
$3,559.14
in general payments reported to CMS, 2019-2025
21 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $317 · 2021: $112 · 2022: $555 · 2023: $543 · 2024: $758 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.51 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.71 | 2019-2025 | |
| Janssen Biotech, INC. | $412.79 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $390.98 | 2019-2025 | |
| Ucb, INC. | $248.01 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $242.47 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $194.72 | 2020-2025 | Nemluvio |
| Lilly USA, LLC | $159.13 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $146.66 | 2022-2025 | |
| Merz North America, INC. | $142.45 | 2020-2023 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $97.78 | 2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $84.37 | 2020-2022 | |
| Genzyme Corporation | $78.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.34 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $57.54 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.34 | 2024-2025 | Cabtreo, Jublia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $48.21 | 2025 | Opzelura |
| Mayne Pharma Commercial LLC | $44.77 | 2022-2024 | |
| Leo Pharma INC. | $34.13 | 2019 | |
| Almirall LLC | $21.54 | 2025 | Seysara |
| Dusa Pharmaceuticals, INC. | $20.80 | 2019 | |
| Kyowa Kirin, INC. | $14.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Mccullem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.